CD30 expression in cutaneous B-cell lymphomas

Area of Science:

• Dermatology
• Oncology
• Pathology

Background:

• CD30 expression is infrequently documented in cutaneous B-cell lymphomas (CBCLs).
• Understanding CD30 expression patterns is crucial for accurate diagnosis and prognosis in CBCLs.
• This study investigates CD30 in various CBCL subtypes and reactive lymphoid hyperplasia (RLH).

Purpose of the Study:

• To examine CD30 expression in a cohort of CBCL and RLH patients.
• To correlate CD30 expression with clinicopathologic features of CBCL.
• To assess the diagnostic and potential therapeutic implications of CD30 in CBCL.

Main Methods:

• CD30 expression was analyzed in 82 CBCL patients and 10 RLH patients.
• CBCL subtypes included primary cutaneous follicle center lymphoma (PCFCL), systemic/nodal follicular lymphoma (SFL), primary cutaneous marginal zone lymphoma (PCMZL/LPD), systemic marginal zone lymphoma (SMZL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT).
• Expression was scored for intensity and extent and correlated with clinical data, including age, sex, PET/CT findings, LDH levels, and bone marrow status.

Main Results:

• CD30 expression was detected in 35% of CBCL cases, varying in intensity and extent.
• Expression was most frequent in PCFCL and absent in PCDLBCL-LT.
• CD30 expression in CBCL was associated with favorable clinical indicators: younger age, negative PET/CT, and normal LDH levels.

Conclusions:

• CD30 can be expressed in CBCL, potentially leading to diagnostic challenges.
• PCFCL most commonly exhibits CD30 expression, linked to favorable prognostic factors.
• Strong and diffuse CD30 expression may represent a therapeutic target in select CBCL cases.